|
1
|
Zhang L, Feng YL, Wang YS and Yang SL:
Modern research status on Evodia rutaecarpa. J Jiangxi Univ
Tradit Chin Med. 22(5)2010.
|
|
2
|
Nam EY, Kim SA, Kim H, Kim SH, Han JH, Lee
JH and Kim DI: Akt activation by Evodiae fructus extract
protects ovary against 4-vinylcyclohexene diepoxide-induced
ovotoxicity. J Ethnopharmacol. 194:733–739. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sui H, Liu X, Jin BH, Pan SF, Zhou LH, Yu
NA, Wu J, Cai JF, Fan ZZ, Zhu HR and Li Q: Zuo Jin Wan, a
traditional Chinese herbal formula, reverses P-gp-mediated MDR in
vitro and in vivo. Evid Based Complement Alternat Med.
2013(957078)2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pan J, Xu Y, Song H, Zhou X, Yao Z and Ji
G: Extracts of Zuo Jin Wan, a traditional Chinese medicine,
phenocopies 5-HTR1D antagonist in attenuating Wnt/β-catenin
signaling in colorectal cancer cells. BMC Complement Altern Med.
17(506)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tang QF, Ji Q, Qiu YY, Cao AL, Chi YF,
Liang B, Peng W and Yin PH: Synergistic effect of Zuo Jin Wan on
DDP-induced apoptosis in human gastric cancer SGC-7901/DDP cells.
Evid Based Complement Alternat Med. 2014(724764)2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Guan X, Zheng X, Vong CT, Zhao J, Xiao J,
Wang Y and Zhong Z: Combined effects of berberine and evodiamine on
colorectal cancer cells and cardiomyocytes in vitro. Eur J
Pharmacol. 875(173031)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chou ST, Hsiang CY, Lo HY, Huang HF, Lai
MT, Hsieh CL, Chiang SY and Ho TY: Exploration of anti-cancer
effects and mechanisms of Zuo-Jin-Wan and its alkaloid components
in vitro and in orthotopic HepG2 xenograft immunocompetent mice.
BMC Complement Altern Med. 17(121)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bae JR, Park WH, Suh DH, No JH, Kim YB and
Kim K: Role of limonin in anticancer effects of evodia rutaecarpa
on ovarian cancer cells. BMC Complement Med Ther.
20(94)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Park E, Lee MY, Seo CS, Jang JH, Kim YU
and Shin HK: Ethanol extract of evodia rutaecarpa attenuates cell
growth through caspase-dependent apoptosis in benign prostatic
hyperplasia-1 cells. Nutrients. 10(523)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gong X, Zhou X, Cai Z, Zhang J and Zhou W:
Studies on chemical constituents of Evodia rutaecarpa.
Zhongguo Zhong Yao Za Zhi. 34:177–179. 2009.PubMed/NCBI(In Chinese).
|
|
11
|
Kim D, Lee YH, Park SH, Lee MJ, Kim MJ,
Jang HS, Lee JM, Lee HY, Han BS, Son WC, et al: Subchronic oral
toxicity of evodia fruit powder in rats. J Ethnopharmacol.
151:1072–1078. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hu X, Li D, Chu C, Li X, Wang X, Jia Y,
Hua H and Xu F: Antiproliferative effects of alkaloid evodiamine
and its derivatives. Int J Mol Sci. 19(3403)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wu JY, Chang MC, Chen CS, Lin HC, Tsai HP,
Yang CC, Yang CH and Lin CM: Topoisomerase I inhibitor evodiamine
acts as an antibacterial agent against drug-resistant Klebsiella
pneumoniae. Planta Med. 79:27–29. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Peng J and Li YJ: The vanilloid receptor
TRPV1: Role in cardiovascular and gastrointestinal protection. Eur
J Pharmacol. 627:1–7. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhao Z, Gong S, Wang S and Ma C: Effect
and mechanism of evodiamine against ethanol-induced gastric ulcer
in mice by suppressing Rho/NF-κB pathway. Int Immunopharmacol.
28:588–595. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yu H, Jin H, Gong W, Wang Z and Liang H:
Pharmacological actions of multi-target-directed evodiamine.
Molecules. 18:1826–1843. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yuan SM, Gao K, Wang DM, Quan XZ, Liu JN,
Ma CM, Qin C and Zhang LF: Evodiamine improves congnitive abilities
in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of
Alzheimer's disease. Acta Pharmacol Sin. 32:295–302.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pan X, Hartley JM, Hartley JA, White KN,
Wang Z and Bligh SW: Evodiamine, a dual catalytic inhibitor of type
I and II topoisomerases, exhibits enhanced inhibition against
camptothecin resistant cells. Phytomedicine. 19:618–624.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huang J, Chen ZH, Ren CM, Wang DX, Yuan
SX, Wu QX, Chen QZ, Zeng YH, Shao Y, Li Y, et al: Antiproliferation
effect of evodiamine in human colon cancer cells is associated with
IGF-1/HIF-1α downregulation. Oncol Rep. 34:3203–3211.
2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhong ZF, Tan W, Wang SP, Qiang WA and
Wang YT: Anti-proliferative activity and cell cycle arrest induced
by evodiamine on paclitaxel-sensitive and -resistant human ovarian
cancer cells. Sci Rep. 5(16415)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q and
Cao P: Evodiamine inhibits STAT3 signaling by inducing phosphatase
shatterproof 1 in hepatocellular carcinoma cells. Cancer Lett.
328:243–251. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wei J, Ching LC, Zhao JF, Shyue SK, Lee
HF, Kou YR and Lee TS: Essential role of transient receptor
potential vanilloid type 1 in evodiamine-mediated protection
against atherosclerosis. Acta Physiol (Oxf). 207:299–307.
2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wanner SP, Garami A, Pakai E, Oliveira DL,
Gavva NR, Coimbra CC and Romanovsky AA: Aging reverses the role of
the transient receptor potential vanilloid-1 channel in systemic
inflammation from anti-inflammatory to proinflammatory. Cell Cycle.
11:343–349. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mezrich JD, Nguyen LP, Kennedy G, Nukaya
M, Fechner JH, Zhang X, Xing Y and Bradfield CA: SU5416, a VEGF
receptor inhibitor and ligand of the AHR, represents a new
alternative for immunomodulation. PLoS One.
7(e44547)2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
O'Donnell EF, Kopparapu PR, Koch DC, Jang
HS, Phillips JL, Tanguay RL, Kerkvliet NI and Kolluri SK: The aryl
hydrocarbon receptor mediates leflunomide-induced growth inhibition
of melanoma cells. PLoS One. 7(e40926)2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shyr MH, Lin LC, Lin TY and Acta TH:
Determination and pharmacokinetics of evodiamine in the plasma and
feces of conscious rats. Anal Chim Acta. 558:16–21. 2006.
|
|
27
|
Lefrak EA, Pitha J, Rosenheim S and
Gottlieb JA: A clinicopathologic analysis of adriamycin
cardiotoxicity. Cancer. 32:302–314. 1973.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Olson RD, Mushlin PS, Brenner DE,
Fleischer S, Cusack BJ, Chang BK and Boucek RJ Jr: Doxorubicin
cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc
Natl Acad Sci USA. 85:3585–3589. 1988.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Stewart DJ, Grewaal D, Green RM, Mikhael
N, Goel R, Montpetit VA and Redmond MD: Concentrations of
doxorubicin and its metabolites in human autopsy heart and other
tissues. Anticancer Res. 13:1945–1952. 1993.PubMed/NCBI
|
|
30
|
Yang W, Ma L, Li S, Cui K, Lei L and Ye Z:
Evaluation of the cardiotoxicity of evodiamine in vitro and in
vivo. Molecules. 22(943)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Huang W, Zhao Y and Sun R: Comparative
study on acute toxicity of different components of Evodia
rutaecarpa in mice. Zhongguo Yao Wu Jing Jie. 7:129–134.
2010.
|
|
32
|
Li F, Dong YZ, Zhang D, Zhang XM, Lin ZJ
and Zhang B: Molecular mechanisms involved in drug-induced liver
injury caused by urate-lowering Chinese herbs: A network
pharmacology study and biology experiments. PLoS One.
14(e0216948)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yan S, Liu Y, Feng J, Zhao H, Yu Z, Zhao
J, Li Y and Zhang J: Difference and alteration in pharmacokinetic
and metabolic characteristics of low-solubility natural medicines.
Drug Metab Rev. 50:140–160. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wen B, Roongta V, Liu L and Moore DJ:
Metabolic activation of the indoloquinazoline alkaloids evodiamine
and rutaecarpine by human liver microsomes: Dehydrogenation and
inactivation of cytochrome P450 3A4. Drug Metab Dispos.
42:1044–1054. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang C, Yue F, Ai G and Yang J:
Simultaneous determination of evodiamine and its four metabolites
in rat plasma by LC-MS/MS and its application to a pharmacokinetic
study. Biomed Chromatogr. 32(e4219)2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Li L, Liu R, Ye M, Hu X, Qiao W, Bi K and
Guo D: Microbial metabolism of evodiamine by penicillium
janthinellum and its application for metabolite identification in
rat urine. Enzyme Microb Technol. 39:561–567. 2006.
|
|
37
|
Jiang J and Hu C: Evodiamine: A novel
anti-cancer alkaloid from evodia rutaecarpa. Molecules.
14:1852–1859. 2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ogasawara M, Matsunaga T, Takahashi S,
Saiki I and Suzuki H: Anti-invasive and metastatic activities of
evodiamine. Biol Pharm Bull. 25:1491–1493. 2002.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chien CC, Wu MS, Shen SC, Ko CH, Chen CH,
Yang LL and Chen YC: Activation of JNK contributes to
evodiamine-induced apoptosis and G2/M arrest in human colorectal
carcinoma cells: A structure-activity study of evodiamine. PLoS
One. 9(e99729)2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Rao L and White E: Bcl-2 and the ICE
family of apoptotic regulators: Making a connection. Curr Opin
Genet Dev. 7:52–58. 1997.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zou Y, Qin X, Xiong H, Zhu F, Chen T and
Wu H: Apoptosis of human non-small-cell lung cancer A549 cells
triggered by evodiamine through MTDH-dependent signaling pathway.
Tumour Biol. 36:5187–5193. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhu LH, Bi W, Liu XD, Li JF, Wu YY, Du BY
and Tan YH: Induction of apoptosis by evodiamine involves both
activation of mitotic arrest and mitotic slippage. Oncol Rep.
26:1447–1455. 2011.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Lee TJ, Kim EJ, Kim S, Jung EM, Park JW,
Jeong SH, Park SE, Yoo YH and Kwon TK: Caspase-dependent and
caspase-independent apoptosis induced by evodiamine in human
leukemic U937 cells. Mol Cancer Ther. 5:2398–2407. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Fei XF, Wang BX, Li TJ, Tashiro S, Minami
M, Xing DJ and Ikejima T: Evodiamine, a constituent of Evodiae
fructus, induces anti-proliferating effects in tumor cells.
Cancer Sci. 94:92–98. 2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhang Y, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Intracellular regulation of evodiamine-induced A375-S2
cell death. Biol Pharm Bull. 26:1543–1547. 2003.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Liu X, Yang L, Bi Y, Wang LH and Huang H:
Effect of evodiamine in inducing apoptosis of gastric cancer
SGC-7901 cells through mTOR signal pathway. Zhongguo Zhong Yao Za
Zhi. 40:3262–3266. 2015.PubMed/NCBI(In Chinese).
|
|
47
|
Yang F, Shi L, Liang T, Ji L, Zhang G,
Shen Y, Zhu F and Xu L: Anti-tumor effect of evodiamine by inducing
Akt-mediated apoptosis in hepatocellular carcinoma. Biochem Biophys
Res Commun. 485:54–61. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Guo XX, Li XP, Zhou P, Li DY, Lyu XT, Chen
Y, Lyu YW, Tian K, Yuan DZ, Ran JH, et al: Evodiamine induces
apoptosis in SMMC-7721 and HepG2 cells by suppressing NOD1 signal
pathway. Int J Mol Sci. 19(3419)2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zhang C, Fan X, Xu X, Yang X, Wang X and
Liang HP: Evodiamine induces caspase-dependent apoptosis and S
phase arrest in human colon lovo cells. Anticancer Drugs.
21:766–776. 2010.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Yang L, Liu X, Wu D, Zhang M, Ran G, Bi Y
and Huang H: Growth inhibition and induction of apoptosis in
SGC-7901 human gastric cancer cells by evodiamine. Mol Med Rep.
9:1147–1152. 2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zhu B, Zhao L, Liu Y, Jin Y, Feng J, Zhao
F, Sun J, Geng R and Wei Y: Induction of phosphatase shatterproof 2
by evodiamine suppresses the proliferation and invasion of human
cholangiocarcinoma. Int J Biochem Cell Biol. 108:98–110.
2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Yang J, Wu LJ, Tashino S, Onodera S and
Ikejima T: Critical roles of reactive oxygen species in
mitochondrial permeability transition in mediating
evodiamine-induced human melanoma A375-S2 cell apoptosis. Free
Radic Res. 41:1099–1108. 2007.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Yang J, Wu LJ, Tashino S, Onodera S and
Ikejima T: Reactive oxygen species and nitric oxide regulate
mitochondria-dependent apoptosis and autophagy in
evodiamine-treated human cervix carcinoma HeLa cells. Free Radic
Res. 42:492–504. 2008.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Wei WT, Chen H, Wang ZH, Ni ZL, Liu HB,
Tong HF, Guo HC, Liu DL and Lin SZ: Enhanced antitumor efficacy of
gemcitabine by evodiamine on pancreatic cancer via regulating
PI3K/Akt pathway. Int J Biol Sci. 8:1–14. 2012.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hong Z, Wang Z, Zhou B, Wang J, Tong H,
Liao Y, Zheng P, Jamshed MB, Zhang Q and Chen H: Effects of
evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in
pancreatic cancer cells. Int J Oncol. 56:783–793. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Wang R, Deng D, Shao N, Xu Y, Xue L, Peng
Y, Liu Y and Zhi F: Evodiamine activates cellular apoptosis through
suppressing PI3K/AKT and activating MAPK in glioma. Onco Targets
Ther. 11:1183–1192. 2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Wang C, Li S and Wang MW:
Evodiamine-induced human melanoma A375-S2 cell death was mediated
by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and
augmented by ubiquitin-proteasome inhibition. Toxicol In Vitro.
24:898–904. 2010.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Wang C, Wang MW, Tashiro S, Onodera S and
Ikejima T: Roles of SIRT1 and phosphoinositide 3-OH kinase/protein
kinase C pathways in evodiamine-induced human melanoma A375-S2 cell
death. J Pharmacol Sci. 97:494–500. 2005.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Huang DM, Guh JH, Huang YT, Chueh SC,
Chiang PC and Teng CM: Induction of mitotic arrest and apoptosis in
human prostate cancer pc-3 cells by evodiamine. J Urol.
173:256–261. 2005.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ and
Wang PS: Anti-proliferative effects of evodiamine on human prostate
cancer cell lines DU145 and PC3. J Cell Biochem. 101:44–56.
2007.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Kan SF, Huang WJ, Lin LC and Wang PS:
Inhibitory effects of evodiamine on the growth of human prostate
cancer cell line LNCaP. Int J Cancer. 110:641–651. 2004.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Liao CH, Pan SL, Guh JH, Chang YL, Pai HC,
Lin CH and Teng CM: Antitumor mechanism of evodiamine, a
constituent from Chinese herb Evodiae fructus, in human
multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro
and in vivo. Carcinogenesis. 26:968–975. 2005.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Rasul A, Yu B, Zhong L, Khan M, Yang H and
Ma T: Cytotoxic effect of evodiamine in SGC-7901 human gastric
adenocarcinoma cells via simultaneous induction of apoptosis and
autophagy. Oncol Rep. 27:1481–1487. 2012.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Graves PR, Yu L, Schwarz JK, Gales J,
Sausville EA, O'Connor PM and Piwnica-Worms H: The Chk1 protein
kinase and the Cdc25C regulatory pathways are targets of the
anticancer agent UCN-01. J Biol Chem. 275:5600–5605.
2000.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Devault A, Martinez AM, Fesquet D, Labbé
JC, Morin N, Tassan JP, Nigg EA, Cavadore JC and Dorée M: MAT1
(‘menage à trois’) a new RING finger protein subunit stabilizing
cyclin H-cdk7 complexes in starfish and Xenopus CAK. EMBO J.
14:5027–5036. 1995.PubMed/NCBI
|
|
66
|
Sun C, Zhang G, Luan S, Luan C, Shao H,
Dong F and Liu X: Evodiamine inhibits the proliferation of leukemia
cell line K562 by regulating peroxisome proliferators-activated
receptor gamma (PPARγ) pathway. J Recept Signal Transduct Res.
36:422–428. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Moosavi F, Giovannetti E, Saso L and
Firuzi O: HGF/MET pathway aberrations as diagnostic, prognostic,
and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci.
56:533–566. 2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Ogasawara M and Suzuki H: Inhibition by
evodiamine of hepatocyte growth factor-induced invasion and
migration of tumor cells. Biol Pharm Bull. 27:578–582.
2004.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Peng X, Zhang Q, Zeng Y, Li J, Wang L and
Ai P: Evodiamine inhibits the migration and invasion of
nasopharyngeal carcinoma cells in vitro via repressing MMP-2
expression. Cancer Chemother Pharmacol. 76:1173–1184.
2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Zhou P, Li XP, Jiang R, Chen Y, Lv XT, Guo
XX, Tian K, Yuan DZ, Lv YW, Ran JH, et al: Evodiamine inhibits
migration and invasion by Sirt1-mediated post-translational
modulations in colorectal cancer. Anticancer Drugs. 30:611–617.
2019.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Shi L, Yang F, Luo F, Liu Y, Zhang F, Zou
M and Liu Q: Evodiamine exerts anti-tumor effects against
hepatocellular carcinoma through inhibiting β-catenin-mediated
angiogenesis. Tumour Biol. 37:12791–12803. 2016.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Shyu KG, Lin S, Lee CC, Chen E, Lin LC,
Wang BW and Tsai SC: Evodiamine inhibits in vitro angiogenesis:
Implication for antitumorgenicity. Life Sci. 78:2234–2243.
2006.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Takada Y, Kobayashi Y and Aggarwal BB:
Evodiamine abolishes constitutive and inducible NF-kappaB
activation by inhibiting IkappaBalpha kinase activation, thereby
suppressing NF-kappaB-regulated antiapoptotic and metastatic gene
expression, up-regulating apoptosis, and inhibiting invasion. J
Biol Chem. 280:17203–17212. 2005.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Li YL, Zhang NY, Hu X, Chen JL, Rao MJ, Wu
LW, Li QY, Zhang B, Yan W and Zhang C: Evodiamine induces apoptosis
and promotes hepatocellular carcinoma cell death induced by
vorinostat via downregulating HIF-1α under hypoxia. Biochem Biophys
Res Commun. 498:481–486. 2018.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Li FS, Huang J, Cui MZ, Zeng JR, Li PP, Li
L, Deng Y, Hu Y, He BC and Shu DZ: BMP9 mediates the anticancer
activity of evodiamine through HIF-1α/p53 in human colon cancer
cells. Oncol Rep. 43:415–426. 2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Kim H, Yu Y, Choi S, Lee H, Yu J, Lee JH
and Kim WY: Evodiamine eliminates colon cancer stem cells via
suppressing notch and Wnt signaling. Molecules.
24(4520)2019.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Wen Z, Feng S, Wei L, Wang Z, Hong D and
Wang Q: Evodiamine, a novel inhibitor of the Wnt pathway, inhibits
the self-renewal of gastric cancer stem cells. Int J Mol Med.
36:1657–1663. 2015.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Yang X, Zhang Y, Huang Y, Wang Y, Qi X, Su
T and Lu L: Evodiamine suppresses Notch3 signaling in lung
tumorigenesis via direct binding to γ-secretases. Phytomedicine.
68(153176)2020.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Su T, Yang X, Deng JH, Huang QJ, Huang SC,
Zhang YM, Zheng HM, Wang Y, Lu LL and Liu ZQ: Evodiamine, a novel
NOTCH3 methylation stimulator, significantly suppresses lung
carcinogenesis in vitro and in vivo. Front Pharmacol.
9(434)2018.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Gai L, Rao GX, Song CQ and Hu ZB: Studies
on the chemical constituents of evodia rutaecarpa (Juss.) Benth.
var. officinalis (Dode) Huang. Yao Xue Xue Bao. 36:743–745.
2001.PubMed/NCBI(In Chinese).
|
|
81
|
Xu S, Peng J, Li Y, He L, Chen F, Zhang J
and Ding J: Pharmacokinetic comparisons of rutaecarpine and
evodiamine after oral administration of Wu-Chu-Yu extracts with
different purities to rats. J Ethnopharmacol. 139:395–400.
2012.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Lin C, Pan X, Li W, Ma J, Pan J, Cai J,
Wang X and Lin G: Simultaneous determination of evodiamine and
rutecarpine in rabbit plasma by LC-ESI-MS and its application to
pharmacokinetics. Pharmazie. 66:920–923. 2011.PubMed/NCBI
|
|
83
|
Xia YY, Xu HY, Cai YY, Si DY and Liu CX:
Simultaneous determination of evodiamine and evodine in beagle dog
plasma using liquid chromatography tandem mass spectrometry. J
Asian Nat Prod Res. 15:235–243. 2013.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Komatsu K, Wakame K and Kano Y:
Pharmacological properties of galenical preparation. XVI.
Pharmacokinetics of evodiamine and the metabolite in rats. Biol
Pharm Bull. 16:935–938. 1993.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Jeng KF, Lin YH, Lin LC, Chou CJ, Tsai TH
and Chen CF: High-performance liquid chromatographic determination
of evodiamine in rat plasma: Application to pharmacokinetic
studies. J Chromatogr B Biomed Appl. 668:343–345. 1995.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Xu H, Li Q, Yin Y, Lv C, Sun W, He B, Liu
R, Chen X and Bi K: Simultaneous determination of three alkaloids,
four ginsenosides and limonin in the plasma of normal and headache
rats after oral administration of Wu-Zhu-Yu decoction by a novel
ultra fast liquid chromatography-tandem mass spectrometry method:
Application to a comparative pharmacokinetics and ethological
study. J Mass Spectrom. 48:519–532. 2013.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Sun HZ, Fang ZZ, Cao YF, Sun XY and Hong
M: Investigation of the in vitro metabolism of evodiamine:
Characterization of metabolites and involved cytochrome p450
isoforms. Phytother Res. 27:705–712. 2013.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Zhang Z, Fang T, Zhou H, Yuan J and Liu Q:
Characterization of the in vitro metabolic profile of evodiamine in
human liver microsomes and hepatocytes by UHPLC-Q exactive mass
spectrometer. Front Pharmacol. 9(130)2018.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Zhang YT, Zhang DF, Ge NY, Zhu GH, Hao C,
Zhang Y and Chen RJ: Effect of evodiamine on CYP enzymes in rats by
a cocktail method. Pharmacology. 97:218–223. 2016.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Xu H, Zhang T, Yang H, Xiao X, Bian Y, Si
D and Liu C: Preparation of evodiamine solid dispersions and its
pharmacokinetics. Indian J Pharm Sci. 73:276–281. 2011.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Tan Q, Liu S, Chen X, Wu M, Wang H, Yin H,
He D, Xiong H and Zhang J: Design and evaluation of a novel
evodiamine-phospholipid complex for improved oral bioavailability.
AAPS PharmSciTech. 13:534–547. 2012.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Grattagliano I, Diogo CV, Mastrodonato M,
de Bari O, Persichella M, Wang DQ, Liquori A, Ferri D, Carratù MR,
Oliveira PJ and Portincasa P: A silybin-phospholipids complex
counteracts rat fatty liver degeneration and mitochondrial
oxidative changes. World J Gastroenterol. 19:3007–3017.
2013.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Hu J, Chen D, Jiang R, Tan Q, Zhu B and
Zhang J: Improved absorption and in vivo kinetic characteristics of
nanoemulsions containing evodiamine-phospholipid nanocomplex. Int J
Nanomedicine. 9:4411–4420. 2014.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Zhao J, Liu S, Hu X, Zhang Y, Yan S, Zhao
H, Zeng M, Li Y, Yang L and Zhang J: Improved delivery of natural
alkaloids into lung cancer through woody oil-based emulsive
nanosystems. Drug Deliv. 25:1426–1437. 2018.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Zhang X, Liu HM, Lei TT, Feng J and Zhang
JQ: A preliminary study of pharmacokinetics of evodiamine
hydroxypropyl-β-cyclodextrin inclusion complex. Nan Fang Yi Ke Da
Xue Xue Bao. 36:548–551. 2016.PubMed/NCBI(In Chinese).
|
|
96
|
Qiu C, Gao LN, Yan K, Cui YL and Zhang Y:
A promising antitumor activity of evodiamine incorporated in
hydroxypropyl-β-cyclodextrin: Pro-apoptotic activity in human
hepatoma HepG2 cells. Chem Cent J. 10(46)2016.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Xu L, Li W, Sadeghi-Soureh S, Amirsaadat
S, Pourpirali R and Alijani S: Dual drug release mechanisms through
mesoporous silica nanoparticle/electrospun nanofiber for enhanced
anticancer efficiency of curcumin. J Biomed Mater Res A, Aug 10,
2021 (Online ahead of print).
|
|
98
|
Rastegari E, Hsiao YJ, Lai WY, Lai YH,
Yang TC, Chen SJ, Huang PI, Chiou SH, Mou CY and Chien Y: An update
on mesoporous silica nanoparticle applications in nanomedicine.
Pharmaceutics. 13(1067)2021.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Feng Y, Li NX, Yin HL, Chen TY, Yang Q and
Wu M: Thermo- and pH-responsive, lipid-coated, mesoporous silica
nanoparticle-based dual drug delivery system to improve the
antitumor effect of hydrophobic drugs. Mol Pharm. 16:422–436.
2019.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Zou L, Chen F, Bao J, Wang S, Wang L, Chen
M, He C and Wang Y: Preparation, characterization, and anticancer
efficacy of evodiamine-loaded PLGA nanoparticles. Drug Deliv.
23:908–916. 2016.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Li C, Cai G, Song D, Gao R, Teng P, Zhou
L, Ji Q, Sui H, Cai J, Li Q and Wang Y: Development of
EGFR-targeted evodiamine nanoparticles for the treatment of
colorectal cancer. Biomater Sci. 7:3627–3639. 2019.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Ge Y, Zhao Y and Li L: Preparation of
sodium cholate-based micelles through non-covalent ıbonding
interaction and application as oral delivery systems for
paclitaxel. Drug Deliv. 23:2555–2565. 2016.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Zhang J, Li Y, Fang X, Zhou D, Wang Y and
Chen M: TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA
delivery in cancer therapy. Int J Pharm. 476:185–198.
2014.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Chen F, Zhang J, He Y, Fang X, Wang Y and
Chen M: Glycyrrhetinic acid-decorated and reduction-sensitive
micelles to enhance the bioavailability and anti-hepatocellular
carcinoma efficacy of tanshinone IIA. Biomater Sci. 4:167–182.
2016.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Jiang J, Liu Y, Wu C, Qiu Y, Xu X, Lv H,
Bai A and Liu X: Development of drug-loaded chitosan hollow
nanoparticles for delivery of paclitaxel to human lung cancer A549
cells. Drug Dev Ind Pharm. 43:1304–1313. 2017.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Wu S, Pan H, Tan S, Ding C, Huang G, Liu
G, Guo J and Su Z: In vitro inhibition of lipid accumulation
induced by oleic acid and in vivo pharmacokinetics of chitosan
microspheres (CTMS) and chitosan-capsaicin microspheres (CCMS).
Food Nutr Res. 61(1331658)2017.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Wang S, Wang L, Shi Z, Zhong Z, Chen M and
Wang Y: Evodiamine synergizes with doxorubicin in the treatment of
chemoresistant human breast cancer without inhibiting
P-glycoprotein. PLoS One. 9(e97512)2014.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Li YL, Pan YN, Wu WJ, Mao SY, Sun J, Zhao
YM, Dong JY, Zhang DY, Pan JP, Zhang C and Lin NM: Evodiamine
induces apoptosis and enhances apoptotic effects of erlotinib in
wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition. Med
Oncol. 33(16)2016.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Pan X, Wang M, Wu Y, Lu X, Shang Y, Xu Y,
Zhai Y, Li J, Li Z and Gong M: Identification of active ingredients
in Wuzhuyu decoction improving migraine in mice by spectral
efficiency association. Mol Med Rep. 12:1524–1534. 2015.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Xu H, Niu H, He B, Cui C, Li Q and Bi K:
Comprehensive qualitative ingredient profiling of chinese herbal
formula Wu-Zhu-Yu decoction via a mass defect and fragment
filtering approach using high resolution mass spectrometry.
Molecules. 21(664)2016.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Wang D, Ge S, Chen Z and Song Y:
Evodiamine exerts anticancer effects via induction of apoptosis and
autophagy and suppresses the migration and invasion of human colon
cancer cells. J BUON. 24:1824–1829. 2019.PubMed/NCBI
|
|
112
|
Zhu LQ, Zhang L, Zhang J, Chang GL, Liu G,
Yu DD, Yu XM, Zhao MS and Ye B: Evodiamine inhibits high-fat
diet-induced colitis-associated cancer in mice through regulating
the gut microbiota. J Integr Med. 19:56–65. 2021.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Ogasawara M, Matsubara T and Suzuki H:
Inhibitory effects of evodiamine on in vitro invasion and
experimental lung metastasis of murine colon cancer cells. Biol
Pharm Bull. 24:917–920. 2001.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Shen H, Zhao S, Xu Z, Zhu L, Han Y and Ye
J: Evodiamine inhibits proliferation and induces apoptosis in
gastric cancer cells. Oncol Lett. 10:367–371. 2015.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Hu C, Gao X, Han Y, Guo Q, Zhang K, Liu M,
Wang Y and Wang J: Evodiamine sensitizes BGC-823 gastric cancer
cells to radiotherapy in vitro and in vivo. Mol Med
Rep. 14:413–419. 2016.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Huang H, Zhang Y, Liu X, Li Z, Xu W, He S,
Huang Y and Zhang H: Acid sphingomyelinase contributes to
evodiamine-induced apoptosis in human gastric cancer SGC-7901
cells. DNA Cell Biol. 30:407–412. 2011.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Sachita K, Kim Y, Yu HJ, Cho SD and Lee
JS: In Vitro assessment of the anticancer potential of evodiamine
in human oral cancer cell lines. Phytother Res. 29:1145–1151.
2015.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Wu Y and Wang J, Zhao J, Zhang Y, Sun Y,
Chen J and Wang J: Gene regulation analysis of the effects of
evodiamine on tongue squamous cell carcinoma. J Cell Biochem.
120:15933–15940. 2019.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Zhao S, Xu K, Jiang R, Li DY, Guo XX, Zhou
P, Tang JF, Li LS, Zeng D, Hu L, et al: Evodiamine inhibits
proliferation and promotes apoptosis of hepatocellular carcinoma
cells via the hippo-yes-associated protein signaling pathway. Life
Sci. 251(117424)2020.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Hu CY, Wu HT, Su YC, Lin CH, Chang CJ and
Wu CL: Evodiamine exerts an anti-hepatocellular carcinoma activity
through a WWOX-dependent pathway. Molecules.
22(1175)2017.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Zhu H, Ge K, Lu J and Jia C: Growth
inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is
associated with downregulation of PRAME. Naunyn Schmiedebergs Arch
Pharmacol. 392:1551–1560. 2019.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Wang XN, Han X, Xu LN, Yin LH, Xu YW, Qi Y
and Peng JY: Enhancement of apoptosis of human hepatocellular
carcinoma SMMC-7721 cells through synergy of berberine and
evodiamine. Phytomedicine. 15:1062–1068. 2008.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Fang C, Zhang J, Qi D, Fan X, Luo J, Liu L
and Tan Q: Evodiamine induces G2/M arrest and apoptosis via
mitochondrial and endoplasmic reticulum pathways in H446 and H1688
human small-cell lung cancer cells. PLoS One.
9(e115204)2014.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Wang T, Qi D, Hu X, Li N, Zhang X, Liu H,
Zhong C and Zhang J: A novel evodiamine amino derivative as a
PI3K/AKT signaling pathway modulator that induces apoptosis in
small cell lung cancer cells. Eur J Pharmacol.
906(174215)2021.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Lin L, Ren L, Wen L, Wang Y and Qi J:
Effect of evodiamine on the proliferation and apoptosis of A549
human lung cancer cells. Mol Med Rep. 14:2832–2838. 2016.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Jiang ZB, Huang JM, Xie YJ, Zhang YZ,
Chang C, Lai HL, Wang W, Yao XJ, Fan XX, Wu QB, et al: Evodiamine
suppresses non-small cell lung cancer by elevating CD8+
T cells and downregulating the MUC1-C/PD-L1 axis. J Exp Clin Cancer
Res. 39(249)2020.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Hong JY, Park SH, Min HY, Park HJ and Lee
SK: Anti-proliferative effects of evodiamine in human lung cancer
cells. J Cancer Prev. 19:7–13. 2014.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Tu YJ, Fan X, Yang X, Zhang C and Liang
HP: Evodiamine activates autophagy as a cytoprotective response in
murine Lewis lung carcinoma cells. Oncol Rep. 29:481–490.
2013.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Mohan V, Agarwal R and Singh RP: A novel
alkaloid, evodiamine causes nuclear localization of cytochrome-c
and induces apoptosis independent of p53 in human lung cancer
cells. Biochem Biophys Res Commun. 477:1065–1071. 2016.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Huang YC, Guh JH and Teng CM: Induction of
mitotic arrest and apoptosis by evodiamine in human leukemic
T-lymphocytes. Life Sci. 75:35–49. 2004.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Zhang Y, Zhang QH, Wu LJ, Tashiro SI,
Onodera S and Ikejima T: Atypical apoptosis in L929 cells induced
by evodiamine isolated from evodia rutaecarpa. J Asian Nat Prod
Res. 6:19–27. 2004.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Khan M, Bi Y, Qazi JI, Fan L and Gao H:
Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death
receptor pathway. Mol Med Rep. 11:257–262. 2015.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Wu WS, Chien CC, Liu KH, Chen YC and Chiu
WT: Evodiamine prevents glioma growth, induces glioblastoma cell
apoptosis and cell cycle arrest through JNK activation. Am J Chin
Med. 45:879–899. 2017.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Liu AJ, Wang SH, Chen KC, Kuei HP, Shih
YL, Hou SY, Chiu WT, Hsiao SH and Shih CM: Evodiamine, a plant
alkaloid, induces calcium/JNK-mediated autophagy and
calcium/mitochondria-mediated apoptosis in human glioblastoma
cells. Chem Biol Interact. 205:20–28. 2013.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Meng ZJ, Wu N, Liu Y, Shu KJ, Zou X, Zhang
RX, Pi CJ, He BC, Ke ZY, Chen L, et al: Evodiamine inhibits the
proliferation of human osteosarcoma cells by blocking PI3K/Akt
signaling. Oncol Rep. 34:1388–1396. 2015.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Zhou Y and Hu J: Evodiamine induces
apoptosis, G2/M cell cycle arrest, and inhibition of cell migration
and invasion in human osteosarcoma cells via Raf/MEK/ERK signalling
pathway. Med Sci Monit. 24:5874–5880. 2018.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Yang S, Chen J, Tan T, Wang N, Huang Y,
Wang Y, Yuan X, Zhang P, Luo J and Luo X: Evodiamine exerts
anticancer effects against 143B and MG63 cells through the
Wnt/β-catenin signaling pathway. Cancer Manag Res. 12:2875–2888.
2020.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Bai X, Meng H, Ma L and Guo A: Inhibitory
effects of evodiamine on human osteosarcoma cell proliferation and
apoptosis. Oncol Lett. 9:801–805. 2015.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Hwang ST, Um JY, Chinnathambi A, Alharbi
SA, Narula AS, Namjoshi OA, Blough BE and Ahn KS: Evodiamine
mitigates cellular growth and promotes apoptosis by targeting the
c-Met pathway in prostate cancer cells. Molecules.
25(1320)2020.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Zhang T, Qu S, Shi Q, He D and Jin X:
Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis
in human bladder cancer cells through mTOR/S6K1-mediated
downregulation of Mcl-1. Int J Mol Sci. 15:3154–3171.
2014.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Shi CS, Li JM, Chin CC, Kuo YH, Lee YR and
Huang YC: Evodiamine induces cell growth arrest, apoptosis and
suppresses tumorigenesis in human urothelial cell carcinoma cells.
Anticancer Res. 37:1149–1159. 2017.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Du J, Sun Y, Lu YY, Lau E, Zhao M, Zhou QM
and Su SB: Berberine and evodiamine Act synergistically against
human breast cancer MCF-7 cells by inducing cell cycle arrest and
apoptosis. Anticancer Res. 37:6141–6151. 2017.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Wang KL, Hsia SM, Yeh JY, Cheng SC, Wang
PS and Wang SW: Anti-proliferative effects of evodiamine on human
breast cancer cells. PLoS One. 8(e67297)2013.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Du J, Wang XF, Zhou QM, Zhang TL, Lu YY,
Zhang H and Su SB: Evodiamine induces apoptosis and inhibits
metastasis in MDA-MB-231 human breast cancer cells in vitro
and in vivo. Oncol Rep. 30:685–694. 2013.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Wei L, Jin X, Cao Z and Li W: Evodiamine
induces extrinsic and intrinsic apoptosis of ovarian cancer cells
via the mitogen-activated protein
kinase/phosphatidylinositol-3-kinase/protein kinase B signaling
pathways. J Tradit Chin Med. 36:353–359. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
146
|
Chen TC, Chien CC, Wu MS and Chen YC:
Evodiamine from evodia rutaecarpa induces apoptosis via activation
of JNK and PERK in human ovarian cancer cells. Phytomedicine.
23:68–78. 2016.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Liu N, Li Y, Chen G and Ge K: Evodiamine
induces reactive oxygen species-dependent apoptosis and necroptosis
in human melanoma A-375 cells. Oncol Lett. 20(121)2020.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Lin H, Lin L, Choi Y and Michniak-Kohn B:
Development and in-vitro evaluation of co-loaded berberine chloride
and evodiamine ethosomes for treatment of melanoma. Int J Pharm.
581(119278)2020.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Yang J, Wu LJ, Tashiro S, Onodera S and
Ikejima T: Nitric oxide activated by p38 and NF-kappaB facilitates
apoptosis and cell cycle arrest under oxidative stress in
evodiamine-treated human melanoma A375-S2 cells. Free Radic Res.
42:1–11. 2008.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Wang C, Wang MW, Tashiro S, Onodera S and
Ikejima T: Evodiamine induced human melanoma A375-S2 cell death
partially through interleukin 1 mediated pathway. Biol Pharm Bull.
28:984–989. 2005.PubMed/NCBI View Article : Google Scholar
|
